[1] |
Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med, 2013, 34(1): 87-94. doi:10.1055/s-0033-1333567.
pmid: 23460008
|
[2] |
Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis, 2016, 45: 123-34. doi:10.1016/j.ijid.2016.03.006.
pmid: 26976549
|
[3] |
Honda JR, Virdi R, Chan ED. Global Environmental Nontuberculous Mycobacteria and Their Contemporaneous Man-Made and Natural Niches. Front Microbiol, 2018, 9: 2029. doi:10.3389/fmicb.2018.02029.
pmid: 30214436
|
[4] |
Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother, 2012, 67(4): 810-818. doi:10.1093/jac/dkr578.
pmid: 22290346
|
[5] |
Howard ST. Recent progress towards understanding genetic variation in the Mycobacterium abscessus complex. Tuberculosis (Edinb), 2013, 93 Suppl: S15-20. doi:10.1016/S1472-9792(13)70005-2.
|
[6] |
Medjahed H, Gaillard JL, Reyrat JM. Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol, 2010, 18(3): 117-123. doi:10.1016/j.tim.2009.12.007.
pmid: 20060723
|
[7] |
张洁, 苏建荣, 丁北川, 等. 北京地区非结核分枝杆菌菌种分布及耐药性研究. 中华结核和呼吸杂志, 2017, 40(3): 210-214. doi:10.3760/cma.j.issn.1001-0939.2017.03.013.
|
[8] |
Nie W, Duan H, Huang H, et al. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates. Biomed Res Int, 2015, 2015: 506598. doi:10.1155/2015/506598.
|
[9] |
Nie W, Duan H, Huang H, et al. Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics. Int J Infect Dis, 2014, 25: 170-174. doi:10.1016/j.ijid.2014.02.014.
|
[10] |
聂文娟, 段鸿飞, 黄海荣, 等. 脓肿分枝杆菌菌种鉴定及药物敏感试验研究. 中华结核和呼吸杂志, 2014, 37(7): 517-521. doi:10.3760/cma.j.issn.1001-0939.2014.07.008.
|
[11] |
Thangavelu K, Krishnakumariamma K, Pallam G, et al. Prevalence and speciation of non-tuberculous mycobacteria among pulmonary and extrapulmonary tuberculosis suspects in South India. J Infect Public Health, 2021, 14(3): 320-323. doi:10.1016/j.jiph.2020.12.027.
|
[12] |
Yao R, Wang B, Fu L, et al. Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis. Microbiol Spectr, 2022, 10(1): e0247721. doi:10.1128/spectrum.02477-21.
|
[13] |
Zhu R, Shang Y, Chen S, et al. In Vitro Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, China. Microbiol Spectr, 2022, 10(6): e0137222. doi:10.1128/spectrum.01372-22.
|
[14] |
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4): 367-416. doi:10.1164/rccm.200604-571ST.
|
[15] |
崔小川, 李琪, 周敏. 肺移植与阻塞性睡眠呼吸暂停. 中华结核和呼吸杂志, 2021, 44(3):257-260. doi:10.3760/cma.j.cn112147-20200606-00682.
|
[16] |
Yang JH, Wang PH, Pan SW, et al. Treatment Outcome in Patients with Mycobacterium abscessus Complex Lung Disease: The Impact of Tigecycline and Amikacin. Antibiotics (Basel), 2022, 11(5): 571. doi:10.3390/antibiotics11050571.
|
[17] |
宋文虎, 端木宏谨. 我国人群中非典型分支杆菌感染调查. 中华结核和呼吸杂志, 1992, 15(6): 333-335.
|
[18] |
Fujita J. Diagnosis and treatment of pulmonary diseases caused by Mycobacterium avium complex. Nihon Rinsho, 2011, 69(8): 1451-1457.
|
[19] |
Kaniga K, Hasan R, Jou R, et al. Bedaquiline Drug Resis-tance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol, 2022, 60(1): e0291920. doi:10.1128/JCM.02919-20.
|
[20] |
聂文娟, 王庆枫, 周文强, 等. 利奈唑胺治疗耐药结核病的有效性和安全性分析. 中国医刊, 2020, 55(8): 891-894. doi:10.3969/j.issn.1008-1070.2020.08.023.
|
[21] |
Cockerill FR, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc, 1991, 66(12):1260-1269. doi:10.1016/s0025-6196(12)62478-1.
pmid: 1749295
|
[22] |
Li AP. Preclinical in vitro screening assays for drug-like pro-perties. Drug Discov Today Technol, 2005, 2(2):179-185. doi:10.1016/j.ddtec.2005.05.024.
|
[23] |
Lu FC. Basic toxicology: Fundamentals, target organs and risk assessment. 3rd ed. Washington: Taylor and Francis, 1996: 27-39.
|
[24] |
Moffett DF, Moffett SB. Human physiology. St. Louis, MO: Mosby, 1993.
|
[25] |
Derelanko MJ, Hollinger. Handbook of toxicology. New York: CRC, 1995: 539-579.
|
[26] |
Rang HP, Dale MM. Pharmacology. London: Churchill Livingstone, 1996.
|
[27] |
Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev, 1997, 29(1/2): 413-580. doi:10.3109/03602539709037591.
|
[28] |
Komatsu T, Yamazaki H, Shimada N, et al. Roles of cytochromes P 450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos, 2000, 28(12): 1457-1463.
pmid: 11095583
|
[29] |
Kurosawa K, Rossenu S, Biewenga J, et al. Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study. J Clin Pharmacol, 2021, 61(10): 1344-1355. doi:10.1002/jcph.1887.
|
[30] |
Wilby KJ. A Scoping Review of the Clinical Pharmacokinetics of Bedaquiline. Clin Pharmacokinet, 2022, 61(4): 481-488. doi:10.1007/s40262-022-01107-4.
|